MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer

Abstract

BackgroundNon-small cell lung cancer (NSCLC) is a leading cause of cancer death worldwide. Early diagnosis is essential for improvements of prognosis and survival of the patients. Currently, there is no effective biomarker available in clinical settings for early detection of lung cancer. Altered expressions in many cancer types including NSCLC and stable existence in plasma make microRNAs (miRNAs) a group of potentially useful biomarkers for clinical assessments of patients with NSCLC.ObjectivesTo evaluate the potential values of miRNAs as blood-based biomarkers for early diagnosis and prognosis in NSCLC patients.MethodsPeripheral blood samples from healthy volunteers and early-staged NSCLC patients before and after surgery were collected, and plasma was separated. Expression of ten miRNAs in the plasma and tumor sections of the patients was detected by quantitative real-time polymerase chain reaction.ResultsMiRNA (miR)-486 and miR-150 were found to significantly distinguish lung cancer patients from healthy volunteers. Area under curve of miR-486 and miR-150 were 0.926 (sensitivity, 0.909; specificity, 0.818) and 0.752 (sensitivity, 0.818; specificity, 0.818), respectively. In response to therapy, patients with down-regulated miR-486 expression showed prolonged recurrence-free survival than those with un-reduced miR-486 expression (median, unreached vs. 19 months; hazard ratio, 0.1053; 95% confidence interval, 0.01045 to 1.060; P=0.056).ConclusionsThe results suggest that miR-486 and miR-150 could be potential blood-based biomarkers for early diagnosis of NSCLC. Monitoring change of miR-486 expression in plasma might be an effective and non-invasive method for recurrence prediction of early-staged NSCLC patients.

Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression

“…Recently, studies have shown that miR-486 was downregulated in lung tumors compared with adjacent uninvolved lung tissues and that miR-486 might play an important role in the development of lung cancer (12,13). In addition, miR-486 has been considered as a biomarker for early diagnosis and recurrence of non-small cell lung cancer (NSCLC) (30). To further explore the related mechanism underlying miR-486 suppression of cell viability and promotion of cell apoptosis, the expression of FOXO 1 and 3, Bim, and pro- and activated caspase-3 was analyzed.…”

miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2

“…Recent studies have shown that dysregulation of miRNA expression contributes to the development and progression of cancer (26)(27)(28). miRNA profiles can also be used as biomarkers for detection of cancer (29)(30)(31)(32)(33)(34) and to predict chemotherapeutic response (35)(36)(37)(38). It is therefore of particular interest to investigate the therapeutic application of miRNAs in lung cancer.…”

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

“…But different studies reported different conclusions about miR-486's regulation in cancers. Some studies reported that miR-486 was reduced in peripheral blood or tissues (27)(28)(29) of lung cancer patients, while others reported that it was up-regulation in lung cancer patients (30) or those patients with up-regulated level miR-486 in plasma had short overall survival (31). Those inconsistent findings were controversial and different study samples selection may be an important reason for this, which needs to be further studied and comprehensively analyzed.…”